in the file that was hosted on Nuklearmedizin website under news, we looked up a price of Euros 23k add VAT of 19% for the treatment. Exchange rate about 1.68, makes A$38,000.
In recent published materials and conference calls etc, it was clearly talk of that Germany has up to 36 University hospitals or similar on the list of enrolment for this new paid study which we all waiting for to commence there.
If in 36 hospitals let's say 10 treatments in total take place per month, you have 120 treatments per year. But it could be more. ( 120 x $38k = $4,560,000 per year ) To make it clear, the Krankenkassen, or public re-imbursement system had agreed to pay for these as part of the trial.
It would make a substantial difference to the whole situation immediately. I expect investment funds to jump on, OR an immediate T/O offer to surface similar to what happened at Resapp (RAP) when Pfizer proposed in conjunction with the successful COVID cough trial.
But best of all, patients in Germany will have a new option for treatment that is proven to have advantages in conjunction with chemo or stand-alone.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)